Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Pancreatic Neoplasms 1Lymphoma, B-Cell 1Lung Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

glucarpidase 2safinamide 1sacubitril and valsartan sodium hydrate drug combination 1ripretinib 1mirabegron 1gamma-Glutamyl Hydrolase 1Sitagliptin Phosphate 1Rituximab 1Methotrexate 1Leucovorin 1Lenalidomide 1Eplerenone 1Duration of Therapy 1Cyclophosphamide 1Cilengitide 1Carboxypeptidases 1Bendamustine Hydrochloride 1Azacitidine 13-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Insufficiency × mirabegron × Lymphoid × Clear all
NCT00750620 2013-09-05

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Astellas Pharma Inc

Phase 1 Completed
33 enrolled
Lymphoid

Lymphoma, Follicular, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡